0I3 Stock Overview
A medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0I3 from our risk checks.
Axonics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.50 |
| 52 Week High | US$67.00 |
| 52 Week Low | US$50.50 |
| Beta | 0.83 |
| 11 Month Change | 4.10% |
| 3 Month Change | 7.63% |
| 1 Year Change | 22.12% |
| 33 Year Change | 17.59% |
| 5 Year Change | 166.81% |
| Change since IPO | 418.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -3.7% | -0.5% |
| 1Y | 22.1% | -4.2% | 8.3% |
Return vs Industry: 0I3 exceeded the German Medical Equipment industry which returned -3.8% over the past year.
Return vs Market: 0I3 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| 0I3 volatility | |
|---|---|
| 0I3 Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0I3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0I3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 797 | Ray Cohen | www.axonics.com |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.
Axonics, Inc. Fundamentals Summary
| 0I3 fundamental statistics | |
|---|---|
| Market cap | €3.42b |
| Earnings (TTM) | -€5.38m |
| Revenue (TTM) | €410.83m |
8.4x
P/S Ratio-640.9x
P/E RatioIs 0I3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I3 income statement (TTM) | |
|---|---|
| Revenue | US$431.90m |
| Cost of Revenue | US$101.10m |
| Gross Profit | US$330.81m |
| Other Expenses | US$336.47m |
| Earnings | -US$5.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 76.59% |
| Net Profit Margin | -1.31% |
| Debt/Equity Ratio | 0% |
How did 0I3 perform over the long term?
See historical performance and comparison